{"id":8254,"date":"2015-02-23T13:23:49","date_gmt":"2015-02-23T13:23:49","guid":{"rendered":"https:\/\/heliospectra.com\/blog\/mfn_news\/heliospectra-hires-dr-sue-sisley-as-director-of-medicinal-plant-research\/"},"modified":"2025-10-24T09:21:49","modified_gmt":"2025-10-24T09:21:49","slug":"heliospectra-hires-dr-sue-sisley-as-director-of-medicinal-plant-research","status":"publish","type":"mfn_news","link":"https:\/\/heliospectra.com\/nl\/blog\/mfn_news\/heliospectra-hires-dr-sue-sisley-as-director-of-medicinal-plant-research\/","title":{"rendered":"Heliospectra hires Dr. Sue Sisley as director of medicinal plant research"},"content":{"rendered":"
<\/p>\n

\n

Heliospectra AB (OTCQB: HLSPY, FIRSTNORTH: HELIO), a world leader in intelligent lighting technology for greenhouse cultivation and plant research, today announced that it has hired Dr. Sue Sisley as Director of Medicinal Plant Research.<\/p>\n

\n

<\/strong><\/div>\n

As Director of Medicinal Plant Research at Heliospectra, Dr. Sisley provides the company with “in the field” knowledge and customer feedback. Working with growers to develop scalable medicinal plant growing methodologies, Dr. Sisley oversees data collection and reporting protocol with Heliospectra’s medicinal plant cultivators in the US, Canada and globally.<\/p>\n

Dr. Sisley’s research focuses on the use of medicinal cannabis as an effective treatment option for veterans suffering from chronic post-traumatic stress disorder. Directly in line with Heliospectra’s value to growers, Dr. Sisley is capable of helping Heliospectra’s customers understand what chemical profiles a medicinal plant therapy should express.<\/p>\n

“The light source offers the opportunity to build specific, consistent medicinal plant therapies. I am proud to be associated with such a talented company,” Sisley said. “As the cannabis industry matures, more growers will need to differentiate their product – one way to do that is by supplying PTSD patients with the type of medicine they know helps them live more productive lives.”<\/p>\n

CBD is a vital research element for Dr. Sisley, who is both a practicing physician and a clinical psychologist. “Heliospectra, myself and several growers are involved with CBD rich strain and other medicinal growing projects. Ironically and thankfully, the market is light years ahead of government approval processes—Heliospectra is a part of that cutting edge agriculture movement.”<\/p>\n

“Heliospectra is proud to play an important role in Dr. Sue Sisley’s PTSD work,” said Staffan Hillberg, CEO of Heliospectra. “Combining her groundbreaking research with Heliospectra’s world leading technology proves again how important plants are to human therapy, especially when they can help people live a normal, healthy life.”<\/p>\n

Dr. Sisley earned her BS in Chemistry and Pre-medicine at Northern Arizona University. She completed her medical degree at the University of Arizona College of Medicine followed by a five-year Residency Training at Good Samaritan Regional Medical Center in the fields of Internal Medicine and Psychiatry. With the Multidisciplinary Association for Psychedelic Studies, Dr. Sisley was awarded a research grant to study the safety and efficacy of marijuana as a treatment for post-traumatic stress disorder.<\/p>\n

“Dr. Sue Sisley is an integral part of our staff. Her research grant from the Colorado Board of Health to study the effects of cannabis on those that suffer from PTSD underscores just how important medicinal cannabis is to the market. Heliospectra will continue to support veterans and others that suffer from such debilitating ailments,” said Chris Walker, General Manager of Heliospectra. “As our growers know, precision commercial operations start with the lamp – light is one way to unlock the genetic instructions found in plants and growing healthy, low carbon footprint medicine is the entire industry’s responsibility.”<\/p>\n

GÖTEBORG, Sweden\/SAN FRANCISCO, Calif., Feb. 19, 2014<\/p>\n

Voor meer informatie: <\/strong>
www.heliospectra.com<\/a>
Staffan Hillberg<\/strong>, CEO Heliospectra, +46 708 36 59 44, staffan.hillberg@heliospectra.com <\/a>
Lars Sjögrell<\/strong>, Press Contact, Heliospectra, +46 702 69 53 00, lars.sjogrell@perspective.se<\/a>
Chris Walker<\/strong>, General Manager USA, 520.971.1031, chris.walker@heliospectra.com <\/a>
G&W Brokerage is the company’s Certified Adviser – www.gwkapital.se <\/a>
Heliospectra AB, Box 5401, SE-402 29, Göteborg, Sweden<\/p>\n

De volgende documenten kunnen worden opgehaald uit beQuoted
Heliospectra Pressrelease 2015-02-23 (English).pdf<\/a>
Heliospectra Pressrelease 2015-02-23 (Swedish).pdf<\/a><\/p>\n

<\/p>\n

Over Heliospectra<\/strong>
Heliospectra AB (publ – listed on NASDAQ OMX First North HELIO ISIN SE0005933082 as well as North American ADR OTCQB: HLSPY Cusip: 423281104) Founded in 2006 and specializing in intelligent lighting technology for plant research and greenhouse cultivation. Heliospectra products are based on in-depth knowledge in plant physiology and photosynthesis along with a unique way to utilize modern LED technology. After six years of development in Sweden, the company has now begun to expand into the international market. The company has raised more than $ 15 million in venture capital and has received more than $2.6 million through academic scholarships and grants. It has also received numerous awards for its forward thinking technology. Principal owners: Industrial Fund www.industrifonden.se<\/a>,Midroc www.midroc.se<\/a>;,Weland Steel www.welandstal.se<\/a>;Wood & Hill Investment www.woodhillinvestment.com<\/a>.<\/p>\n

<\/em><\/p>\n

<\/div>\n
\n

Bijlagen<\/strong>
PDF<\/a>
PDF<\/a><\/p>\n<\/div>\n